JP2022544825A5 - - Google Patents

Info

Publication number
JP2022544825A5
JP2022544825A5 JP2022510857A JP2022510857A JP2022544825A5 JP 2022544825 A5 JP2022544825 A5 JP 2022544825A5 JP 2022510857 A JP2022510857 A JP 2022510857A JP 2022510857 A JP2022510857 A JP 2022510857A JP 2022544825 A5 JP2022544825 A5 JP 2022544825A5
Authority
JP
Japan
Prior art keywords
genetically modified
cells
population
pharmaceutical product
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022510857A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022544825A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/047202 external-priority patent/WO2021035054A1/en
Publication of JP2022544825A publication Critical patent/JP2022544825A/ja
Publication of JP2022544825A5 publication Critical patent/JP2022544825A5/ja
Pending legal-status Critical Current

Links

JP2022510857A 2019-08-20 2020-08-20 細胞免疫療法のためのリンパ球枯渇投与レジメン Pending JP2022544825A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962889338P 2019-08-20 2019-08-20
US62/889,338 2019-08-20
US202063061070P 2020-08-04 2020-08-04
US63/061,070 2020-08-04
PCT/US2020/047202 WO2021035054A1 (en) 2019-08-20 2020-08-20 Lymphodepletion dosing regimens for cellular immunotherapies

Publications (2)

Publication Number Publication Date
JP2022544825A JP2022544825A (ja) 2022-10-21
JP2022544825A5 true JP2022544825A5 (enExample) 2023-08-29

Family

ID=72291163

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022510857A Pending JP2022544825A (ja) 2019-08-20 2020-08-20 細胞免疫療法のためのリンパ球枯渇投与レジメン

Country Status (6)

Country Link
US (1) US20220273720A1 (enExample)
EP (1) EP4017526A1 (enExample)
JP (1) JP2022544825A (enExample)
AU (1) AU2020333851A1 (enExample)
CA (1) CA3148179A1 (enExample)
WO (1) WO2021035054A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20210137085A (ko) 2019-03-05 2021-11-17 엔카르타, 인크. Cd19 유도된 키메라 항원 수용체 및 면역 요법에서 이의 용도
CA3218640A1 (en) * 2021-05-13 2022-11-17 Kanya Lakshmi RAJANGAM Dosing regimens for cancer immunotherapy
AU2022283272A1 (en) * 2021-05-24 2023-12-07 Provention Bio, Inc. Methods for treating post infectious autoimmune diabetes
MX2023013851A (es) 2021-05-24 2023-12-08 Provention Bio Inc Metodos para el tratamiento de diabetes tipo 1.
US20250009800A1 (en) * 2021-11-16 2025-01-09 Precision Biosciences, Inc. Methods for cancer immunotherapy
WO2023108150A1 (en) * 2021-12-10 2023-06-15 Precision Biosciences, Inc. Methods for cancer immunotherapy
EP4773969A1 (en) * 2023-09-08 2026-07-15 Fate Therapeutics, Inc. Ipsc-derived effector cells for autoimmune disease treatment

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5350674A (en) 1992-09-04 1994-09-27 Becton, Dickinson And Company Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof
US6140466A (en) 1994-01-18 2000-10-31 The Scripps Research Institute Zinc finger protein derivatives and methods therefor
JP4012243B2 (ja) 1994-01-18 2007-11-21 ザ スクリップス リサーチ インスティチュート 亜鉛フィンガータンパク質誘導体およびそのための方法
CA2196419C (en) 1994-08-20 2007-08-21 Yen Choo Improvements in or relating to binding proteins for recognition of dna
GB9824544D0 (en) 1998-11-09 1999-01-06 Medical Res Council Screening system
US5789538A (en) 1995-02-03 1998-08-04 Massachusetts Institute Of Technology Zinc finger proteins with high affinity new DNA binding specificities
US7696338B2 (en) 1995-10-30 2010-04-13 The United States Of America As Represented By The Department Of Health And Human Services Immunotoxin fusion proteins and means for expression thereof
US5925523A (en) 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
JP3614866B2 (ja) 1997-06-12 2005-01-26 リサーチ コーポレイション テクノロジーズ，インコーポレイティド 人工抗体ポリペプチド
US6015832A (en) 1997-12-31 2000-01-18 The Regents Of The University Of Michigan Methods of inactivating bacteria including bacterial spores
US6559189B2 (en) 1999-04-28 2003-05-06 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
US7767216B2 (en) 1999-04-28 2010-08-03 The Regents Of The University Of Michigan Antimicrobial compositions and methods of use
US6506803B1 (en) 1999-04-28 2003-01-14 Regents Of The University Of Michigan Methods of preventing and treating microbial infections
US6635676B2 (en) 1999-04-28 2003-10-21 Regents Of The University Of Michigan Non-toxic antimicrobial compositions and methods of use
EP1235842A4 (en) 1999-10-15 2003-04-23 Univ Massachusetts Rna interference pathway genes as tools for targeted genetic interference
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
US20020061512A1 (en) 2000-02-18 2002-05-23 Kim Jin-Soo Zinc finger domains and methods of identifying same
AU2001263155A1 (en) 2000-05-16 2001-11-26 Massachusetts Institute Of Technology Methods and compositions for interaction trap assays
WO2001096584A2 (en) 2000-06-12 2001-12-20 Akkadix Corporation Materials and methods for the control of nematodes
US6555674B2 (en) 2000-08-09 2003-04-29 Nsgene A/S JeT promoter
GB0108491D0 (en) 2001-04-04 2001-05-23 Gendaq Ltd Engineering zinc fingers
ATE347593T1 (de) 2002-01-23 2006-12-15 Univ Utah Res Found Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen
EP1504092B2 (en) 2002-03-21 2014-06-25 Sangamo BioSciences, Inc. Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
US7074596B2 (en) 2002-03-25 2006-07-11 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Synthesis and use of anti-reverse mRNA cap analogues
US9447434B2 (en) 2002-09-05 2016-09-20 California Institute Of Technology Use of chimeric nucleases to stimulate gene targeting
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US8409861B2 (en) 2003-08-08 2013-04-02 Sangamo Biosciences, Inc. Targeted deletion of cellular DNA sequences
SG188175A1 (en) 2004-06-03 2013-03-28 Novimmune Sa Anti-cd3 antibodies and methods of use thereof
EP1913149A4 (en) 2005-07-26 2009-08-05 Sangamo Biosciences Inc TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES
PL2578685T3 (pl) 2005-08-23 2020-01-31 The Trustees Of The University Of Pennsylvania Rna zawierający zmodyfikowane nukleozydy i sposoby jego zastosowania
DK3246403T3 (da) 2005-10-18 2020-10-26 Prec Biosciences Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet
ES2422291T3 (es) 2007-10-31 2013-09-10 Prec Biosciences Inc Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas
EP2206723A1 (en) 2009-01-12 2010-07-14 Bonas, Ulla Modular DNA-binding domains
WO2011059836A2 (en) 2009-10-29 2011-05-19 Trustees Of Dartmouth College T cell receptor-deficient t cell compositions
JP5956342B2 (ja) 2009-11-03 2016-07-27 シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ）
US8956828B2 (en) 2009-11-10 2015-02-17 Sangamo Biosciences, Inc. Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
PT2816112T (pt) 2009-12-10 2018-11-20 Univ Iowa State Res Found Inc Modificação do adn modificada pelo efector tal
US20140115726A1 (en) 2011-04-05 2014-04-24 Cellectis New tale-protein scaffolds and uses thereof
GB201206559D0 (en) 2012-04-13 2012-05-30 Ucl Business Plc Polypeptide
EP3498305A1 (en) 2012-04-20 2019-06-19 Angimmune Llc Immunomodulation by anti-cd3 immunotoxins to treat cancers not uniformly bearing surface cd3
SG10201806573TA (en) * 2012-05-25 2018-09-27 Cellectis Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
AU2014235968B2 (en) 2013-03-21 2018-05-24 Ospedale San Raffaele Srl Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases
CA2913872C (en) 2013-05-31 2022-01-18 Cellectis A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof
US9790490B2 (en) 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
ES2803728T3 (es) 2015-10-05 2021-01-29 Prec Biosciences Inc Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado
ES2768984T3 (es) 2015-10-05 2020-06-24 Prec Biosciences Inc Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas
EP3504241B1 (en) 2016-08-29 2024-05-15 Tiziana Life Sciences PLC Anti-cd3 antibody formulations
DK3757120T3 (da) 2016-10-04 2022-07-25 Prec Biosciences Inc Co-stimulerende domæner til anvendelse i genetisk modificerede celler
EP3692057B9 (en) 2017-10-03 2023-10-04 Precision BioSciences, Inc. Modified epidermal growth factor receptor peptides for use in genetically-modified cells
EP4069285A1 (en) * 2019-12-06 2022-10-12 Precision BioSciences, Inc. Methods for cancer immunotherapy, using lymphodepletion regimens and cd19, cd20 or bcma allogeneic car t cells

Similar Documents

Publication Publication Date Title
Tapia-Galisteo et al. Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies
Duell et al. Bispecific antibodies in the treatment of hematologic malignancies
Goebeler et al. T cell-engaging therapies—BiTEs and beyond
Stein et al. Blinatumomab for acute lymphoblastic leukemia relapse after allogeneic hematopoietic stem cell transplantation
Zekri et al. An IgG‐based bispecific antibody for improved dual targeting in PSMA‐positive cancer
Aldoss et al. Redirecting T cells to eradicate B-cell acute lymphoblastic leukemia: bispecific T-cell engagers and chimeric antigen receptors
Shabaneh et al. Systemically administered low-affinity HER2 CAR T cells mediate antitumor efficacy without toxicity
US20260102510A1 (en) Conditioning for in vivo immune cell engineering
JP7573441B2 (ja) ガイダンス及びナビゲーションコントロール蛋白質並びにその生産及び使用方法
JP2022159548A5 (enExample)
US20240041930A1 (en) Methods and compositions for dosing of allogeneic chimeric antigen receptor t cells
Zhang et al. Activating Fc receptors are required for antitumor efficacy of the antibodies directed toward CD25 in a murine model of adult T-cell leukemia
US20230270857A1 (en) Compositions including ex vivo armed t cells with multi-specific antibodies and uses thereof
Wang et al. Nanobody-armed T cells endow CAR-T cells with cytotoxicity against lymphoma cells
JP2015163068A5 (enExample)
Guo et al. Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment
JP2022513689A5 (enExample)
JP2023537002A5 (enExample)
JP2020502147A (ja) 制御性ｂ１０細胞を枯渇させる抗体および方法並びに免疫チェックポイント阻害剤との併用における使用
Lyons et al. Bispecific T-cell engagers in childhood B-acute lymphoblastic leukemia
JP2024518776A5 (enExample)
Castaneda-Puglianini et al. Bispecific antibodies for non-Hodgkin’s lymphomas and multiple myeloma
JP2023540255A5 (enExample)
JP2021529776A5 (enExample)
JP2024038034A (ja) 膀胱癌の抗ｐｄ－ｌ１抗体治療